Launch of International NOBLE Registry for SPECT Imaging
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces today the launch of the international NOBLE Registry of Telix’s 99m ‘rest of world’ prostate cancer imaging agent TLX599-CDx ( Tc-HYNIC-iPSMA), and the dosing of the first patient at the University College Hospital, Ibadan (Nigeria). The aim of the NOBLE (Nobody Left
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- TGA commences priority evaluation process for Illuccix
- S&P DJI Announces March 2021 Quarterly Rebalance
- Appendix 4E - Results for announcement to the market
- Shareholder update - year ended 31 December 2020
- Czech Republic Grants National Authorisation for TLX591 Kit
Later from Telix Pharmaceuticals
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
- Activities Report and App 4C for quarter ended 31 March 2021
- Phase III Prostate Cancer Therapy Clinical Trial Commences
- German Distribution Agreement with Eckert and Ziegler
- TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals